Chemomab Therapeutics (CMMB) Competitors $1.20 -0.10 (-7.48%) Closing price 06/11/2025 03:59 PM EasternExtended Trading$1.20 +0.00 (+0.02%) As of 08:57 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CMMB vs. STRO, EPIX, PYXS, ADAP, IGMS, TNYA, IMMX, INCR, ELUT, and PYRGFShould you be buying Chemomab Therapeutics stock or one of its competitors? The main competitors of Chemomab Therapeutics include Sutro Biopharma (STRO), ESSA Pharma (EPIX), Pyxis Oncology (PYXS), Adaptimmune Therapeutics (ADAP), IGM Biosciences (IGMS), Tenaya Therapeutics (TNYA), Immix Biopharma (IMMX), InterCure (INCR), Elutia (ELUT), and PyroGenesis Canada (PYRGF). These companies are all part of the "pharmaceutical products" industry. Chemomab Therapeutics vs. Its Competitors Sutro Biopharma ESSA Pharma Pyxis Oncology Adaptimmune Therapeutics IGM Biosciences Tenaya Therapeutics Immix Biopharma InterCure Elutia PyroGenesis Canada Chemomab Therapeutics (NASDAQ:CMMB) and Sutro Biopharma (NASDAQ:STRO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, community ranking, analyst recommendations and profitability. Does the media prefer CMMB or STRO? In the previous week, Chemomab Therapeutics and Chemomab Therapeutics both had 2 articles in the media. Sutro Biopharma's average media sentiment score of 1.78 beat Chemomab Therapeutics' score of 0.93 indicating that Sutro Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Chemomab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sutro Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Does the MarketBeat Community believe in CMMB or STRO? Sutro Biopharma received 112 more outperform votes than Chemomab Therapeutics when rated by MarketBeat users. However, 66.67% of users gave Chemomab Therapeutics an outperform vote while only 63.46% of users gave Sutro Biopharma an outperform vote. CompanyUnderperformOutperformChemomab TherapeuticsOutperform Votes2066.67% Underperform Votes1033.33% Sutro BiopharmaOutperform Votes13263.46% Underperform Votes7636.54% Which has more risk & volatility, CMMB or STRO? Chemomab Therapeutics has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. Comparatively, Sutro Biopharma has a beta of 1.7, meaning that its share price is 70% more volatile than the S&P 500. Which has higher earnings and valuation, CMMB or STRO? Chemomab Therapeutics has higher earnings, but lower revenue than Sutro Biopharma. Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChemomab TherapeuticsN/AN/A-$24.22M-$0.76-1.58Sutro Biopharma$66.43M1.05-$106.79M-$2.98-0.28 Do analysts recommend CMMB or STRO? Chemomab Therapeutics currently has a consensus target price of $8.50, indicating a potential upside of 606.74%. Sutro Biopharma has a consensus target price of $6.11, indicating a potential upside of 639.51%. Given Sutro Biopharma's higher probable upside, analysts plainly believe Sutro Biopharma is more favorable than Chemomab Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chemomab Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Sutro Biopharma 1 Sell rating(s) 5 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.13 Is CMMB or STRO more profitable? Chemomab Therapeutics has a net margin of 0.00% compared to Sutro Biopharma's net margin of -77.01%. Chemomab Therapeutics' return on equity of -101.70% beat Sutro Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Chemomab TherapeuticsN/A -101.70% -76.18% Sutro Biopharma -77.01%-101.89%-28.69% Do institutionals & insiders hold more shares of CMMB or STRO? 46.0% of Chemomab Therapeutics shares are owned by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are owned by institutional investors. 11.9% of Chemomab Therapeutics shares are owned by company insiders. Comparatively, 3.6% of Sutro Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummarySutro Biopharma beats Chemomab Therapeutics on 8 of the 15 factors compared between the two stocks. Get Chemomab Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMMB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CMMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMMB vs. The Competition Export to ExcelMetricChemomab TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.68M$6.85B$5.57B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-1.208.7827.1420.06Price / SalesN/A255.49419.32157.08Price / CashN/A65.8538.2534.64Price / Book0.786.557.064.70Net Income-$24.22M$143.93M$3.23B$247.88M7 Day Performance-8.89%3.84%2.83%2.63%1 Month Performance-3.01%11.20%9.02%6.36%1 Year Performance9.84%4.18%31.36%14.05% Chemomab Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMMBChemomab Therapeutics3.605 of 5 stars$1.20-7.5%$8.50+606.7%+20.3%$22.68MN/A-1.2020News CoverageSTROSutro Biopharma4.6103 of 5 stars$0.90+0.8%$6.11+575.8%-78.4%$76.42M$66.43M-0.56240Positive NewsGap DownEPIXESSA Pharma2.0111 of 5 stars$1.71+1.8%$2.00+17.0%-69.1%$75.91MN/A-2.4850News CoveragePositive NewsPYXSPyxis Oncology2.2686 of 5 stars$1.22+0.8%$9.00+637.7%-67.4%$75.58M$16.15M-1.1860ADAPAdaptimmune Therapeutics3.3367 of 5 stars$0.28-2.6%$1.52+432.9%-73.8%$75.51M$179.64M-1.30490Positive NewsIGMSIGM Biosciences4.4932 of 5 stars$1.26-0.8%$5.50+336.5%-84.2%$75.32M$2.68M-0.35190TNYATenaya Therapeutics3.7204 of 5 stars$0.46flat$6.25+1,258.7%-82.9%$74.83MN/A-0.32110News CoverageIMMXImmix Biopharma2.7082 of 5 stars$2.60+11.1%$7.00+169.2%+19.1%$72.48MN/A-3.069Short Interest ↑Gap UpHigh Trading VolumeINCRInterCure0.2901 of 5 stars$1.59+1.5%N/A-36.3%$72.46M$238.85M0.00350Short Interest ↑ELUTElutia3.8421 of 5 stars$1.76-2.2%$8.00+354.5%-49.3%$72.36M$23.71M-0.67180News CoverageAnalyst RevisionPYRGFPyroGenesis Canada0.1709 of 5 stars$0.39-2.0%N/A-20.8%$71.93M$9.14M-6.4290Short Interest ↑Gap Down Related Companies and Tools Related Companies STRO Competitors EPIX Competitors PYXS Competitors ADAP Competitors IGMS Competitors TNYA Competitors IMMX Competitors INCR Competitors ELUT Competitors PYRGF Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CMMB) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chemomab Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chemomab Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
